References
1. Khaddour, K., C.K. Hana, and P. Mewawalla, Hematopoietic stem cell transplantation. 2019.
2. Gratwohl, A., et al.,Hematopoietic stem cell transplantation: a global perspective.Jama, 2010. 303 (16): p. 1617-1624.
3. Bazinet, A. and G. Popradi, A general practitioner’s guide to hematopoietic stem-cell transplantation. Current Oncology, 2019. 26 (3): p. 187-191.
4. Finefrock, D., et al.,Process for Delivering Timely Antibiotics to Febrile Bone Marrow Transplant Patients in the Emergency Department. JCO Oncology Practice, 2021: p. OP. 20.00430.
5. Kuderer, N.M., et al.,Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 2006. 106 (10): p. 2258-2266.
6. Kyriacou, D.N., B. Jovanovic, and O. Frankfurt, Timing of initial antibiotic treatment for febrile neutropenia in the emergency department: the need for evidence-based guidelines. Journal of the National Comprehensive Cancer Network, 2014.12 (11): p. 1569-1573.
7. Lin, M.Y., R.A. Weinstein, and B. Hota, Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrobial agents and chemotherapy, 2008. 52 (9): p. 3188-3194.
8. Michallet, M. and J.I. Ito,Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. Journal of clinical oncology, 2009. 27 (20): p. 3398-3409.
9. Cordonnier, C., et al.,Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clinical infectious diseases, 2009. 48 (8): p. 1042-1051.
10. Walsh, T.J., et al.,Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New England Journal of Medicine, 1999. 340 (10): p. 764-771.
11. Moen, M.D., K.A. Lyseng-Williamson, and L.J. Scott, Liposomal amphotericin B.Drugs, 2009. 69 (3): p. 361-392.
12. Cornely, O., Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection, 2008. 36 (4): p. 296-313.
13. Lemke, A., A. Kiderlen, and O. Kayser, Amphotericin b. Applied microbiology and biotechnology, 2005. 68 (2): p. 151-162.
14. Stone, N.R., et al.,Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs, 2016. 76 (4): p. 485-500.
15. Kelsey, P., et al.,Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma—a retrospective study from the BSBMT (BEAM versus LEAM). Bone marrow transplantation, 2021.56 (3): p. 730-732.
16. Coukell, A.J. and R.N. Brogden,Liposomal amphotericin B. Drugs, 1998. 55 (4): p. 585-612.
17. Naranjo, C.A., et al., A method for estimating the probability of adverse drug reactions.Clinical Pharmacology & Therapeutics, 1981. 30 (2): p. 239-245.
18. Küppers, R., A. Engert, and M.-L. Hansmann, Hodgkin lymphoma. The Journal of clinical investigation, 2012. 122 (10): p. 3439-3447.
19. Willasch, A.M., et al.,Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study. Bone marrow transplantation, 2020. 55 (8): p. 1540-1551.
20. Cagnoni, P.J., Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Antimicrobial Chemotherapy, 2002. 49 (suppl_1): p. 81-86.
21. Mukhtar, M., et al., Case report: First report on ambisome-associated allergic reaction in two Sudanese leishmaniasis patients. The American journal of tropical medicine and hygiene, 2011. 85 (4): p. 644.
22. Mukhtar, M., Amphotericin B liposomal Allergic reaction: 2 case reports. Reactions, 2012.1383 : p. 7.
23. Nath, P., et al., Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Tropical doctor, 2014. 44 (4): p. 241-242.
24. Sunakawa, K., et al.,Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children. Journal of Infection and Chemotherapy, 2012.18 (4): p. 456-465.
Table1 : vital signs before, at end of infusion and after Ambisome administration